U
OREX

UBS’s Orexigen Therapeutics, Inc. OREX Stock Holding History

UBS’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$11K Sell
260
-630
-71% -$33.8K ﹤0.01% 8801
2014
Q2 		$55K Buy
890
+880
+8,800% +$51.2K ﹤0.01% 6744
2014
Q1 		$1K Sell
10
-2,030
-100% -$137K ﹤0.01% 10341
2013
Q4 		$115K Buy
2,040
+140
+7% +$7.87K ﹤0.01% 5914
2013
Q3 		$116K Sell
1,900
-200
-10% -$13.5K ﹤0.01% 5847
2013
Q2 		$123K Buy
+2,100
New +$129K ﹤0.01% 5661

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's OREX Position: Q3 2014 in Review

UBS reduced its Orexigen Therapeutics, Inc. (OREX) stake by 12% in Q3 2014, selling an estimated $90.3K and leaving 11,978 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #4259.

UBS first reported a position in OREX in Q2 2013 and has held it in 6 quarters since. The position peaked at $999K in Q1 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

  • UBS held 11,978 shares of Orexigen Therapeutics, Inc. worth $510K as of Q3 2014.
  • UBS sold 1,682 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $90.3K.
  • Orexigen Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4259 holding.
  • UBS first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Orexigen Therapeutics, Inc. position peaked at $999K in Q1 2014.
  • 128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.